Trends in Cardio-Oncology & the Implications for Detecting Cardiac Toxicity in Clinical Trials, Upcoming Webinar Hosted by Xtalks

A greater understanding of molecular pathways that govern carcinogenesis has led to the investigation of targeted agents in clinical studies. However, some of these targeted agents can cause various cardiovascular complications which must be monitored and managed during early-phase studies. In this free webinar, learn about trends in cardiac toxicity in oncology clinical trials and learn how core laboratories are standardizing data collection techniques.

TORONTO (PRWEB) May 13, 2019 -- Join Dr. Tim Callahan, Vice President of Scientific Affairs at BioTel Research in a live webinar on Thursday, May 30, 2019 at 1pm EDT to learn about:

• Trends in cardio-oncology
• Perspectives from regulatory, academia and industry
• Recommendations regarding the prediction, avoidance and detection of CV safety events in oncologic drug development
• Reducing variability in electrocardiogram/echocardiogram data acquisition and analysis

In recent years, the development of clinical trials using targeted agents has been stimulated by the identification of pathways involved in carcinogenesis, metastasis and drug resistance and by the emergence of molecular analysis of tumors. These targeted agents are initially investigated as single agents in phase I clinical trials, and, if well tolerated, in phase II and III studies. However, some targeted agents can cause arrhythmia, hypertension, ischemia or left ventricular (LV) dysfunction. Because determining the maximum tolerated dose and dose-limiting toxicity are primary endpoints of phase I clinical trials, many useful targeted agents that cause excess cardiac toxicity might not proceed to phase II trials. Therefore, cardiac risk factors should be taken into account in the selection and management of patients with cancer who are enrolled in phase I clinical trials.

Centralizing electrocardiograms and echocardiograms have become the industry standard for collecting and analyzing these data. Core laboratories act to reduce variability by standardizing collection techniques and reading paradigms. The reduction in variability can result in fewer false positive readings for the sponsor.

For more information or to register for this event, visit Trends in Cardio-Oncology & the Implications for Detecting Cardiac Toxicity in Clinical Trials.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com.
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

PRWeb ebooks - Another online visibility tool from PRWeb
Contact Information
Candice Tang
Xtalks
http://www.xtalks.com
4169776555

Online Web 2.0 Version
You can read the online version of this press release here.